Under the agreement, financial terms of which were not made public, will see Mumbai, India-based Lupin develop “multiple” paediatric pharmaceutical products using the PharmFilm technology.
MonoSol RX’s technology is designed to rapidly dissolve on the tongue and release active pharmaceutical ingredients (API). It is intended for patients who have difficulty swallowing conventional medications.
In a Bombay Stock Exchange (BSE) filing Lupin said the deal fits with is focus on the “specialty pharmaceutical market, and specifically, pediatric needs such as attention-deficit/hyperactivity disorder (ADHD).”
The deal comes a few months after Lupin acquired Gavis Pharmaceuticals. The takeover included a facility in New Jersey, US at which Gavis’ subsidiary Novel Laboratories makes schedule II to V drugs.
Lupin is the third firm to license MonoSol Rx’s film technology this year.
In April Cynapsus Therapeutics licensed related IP to films containing apomorphine with the aim of developing a treatment for Parkinson’s disease patients.
In July, unrelated namesake company MonoSol Llc licensed rights to use the film technology to develop products for the agrochemical and water treatment sectors.
In addition, last December Midatech bought an anti-emetic formulated using the PharmFilm tech – called Zuplenz – from former MonoSol Rx licensee Galena Biopharma.
Zuplenz – one of two commercial products formulated using the technology alongside the opioid dependence treatment Suboxone – was previously licensed by Par Pharmaceutical subsidiary Strativa, which handed back rights to the drug in 2011.